Home World News Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma World News Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 1074 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Learning to Live With Cancer: A Survivor’s Story November 30, 2023 ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... October 13, 2025 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 Mohs Surgery for Skin Cancer: What to Know and What to... March 28, 2023 Load more HOT NEWS Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of... Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... Male Patients with Cancer at Higher Risk of Severe Disease Course... Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes
